KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $57.4 billion.

  • Pfizer's Non-Current Debt fell 102.24% to $57.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $57.4 billion, marking a year-over-year decrease of 102.24%. This contributed to the annual value of $57.4 billion for FY2024, which is 741.13% down from last year.
  • Pfizer's Non-Current Debt amounted to $57.4 billion in Q3 2025, which was down 102.24% from $57.5 billion recorded in Q2 2025.
  • Over the past 5 years, Pfizer's Non-Current Debt peaked at $62.0 billion during Q4 2023, and registered a low of $31.7 billion during Q2 2023.
  • In the last 5 years, Pfizer's Non-Current Debt had a median value of $57.4 billion in 2024 and averaged $47.5 billion.
  • As far as peak fluctuations go, Pfizer's Non-Current Debt crashed by 3003.23% in 2021, and later skyrocketed by 9337.31% in 2024.
  • Quarter analysis of 5 years shows Pfizer's Non-Current Debt stood at $36.2 billion in 2021, then decreased by 8.83% to $33.0 billion in 2022, then skyrocketed by 87.88% to $62.0 billion in 2023, then fell by 7.41% to $57.4 billion in 2024, then rose by 0.01% to $57.4 billion in 2025.
  • Its last three reported values are $57.4 billion in Q3 2025, $57.5 billion for Q2 2025, and $57.6 billion during Q1 2025.